Monoclonal antibodies against IL-5 (mepolizumab, reslizumab) and IL-5R (benralizumab) have been reported to dramatically decrease blood eosinophil counts in asthma patients [58–60] and in patients with hypereosinophilic syndrome (HES) [61]. This evidence concerns the gene IL5 and hypereosinophilic syndrome.